Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
HB-EGF CRISPR/Cas9 KO Plasmid (h): sc-400795
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HB-EGF CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the HB-EGF genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: HB-EGF Antibody (G-11): sc-74441
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HB-EGF CRISPR/Cas9 KO Plasmid (h) | sc-400795 | 20 µg | $397.00 |
Overview
HBEGF encodes heparin-binding EGF-like growth factor (HB-EGF), a membrane-anchored ligand that can be released by proteolytic shedding to signal through EGFR/ERBB family receptors. HB-EGF activates downstream MAPK/ERK, PI3K–AKT, and related mitogenic and survival pathways that regulate epithelial and stromal cell proliferation, migration, and wound-response programs. This axis is frequently studied in contexts of aberrant EGFR signaling, including tumor biology, inflammatory remodeling, and vascular and cardiac stress responses. HBEGF expression dynamics also intersect with ADAM metalloprotease activity and paracrine/autocrine growth factor networks that shape tissue microenvironments.
HB-EGF CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the HBEGF gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the HBEGF together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the HBEGF open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish HB-EGF protein expression.
This CRISPR knockout system enables efficient generation of HBEGF-deficient cell models for investigation of HB-EGF signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting HBEGF exon(s) critical for HB-EGF function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple HBEGF genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by HB-EGF CRISPR/Cas9 KO Plasmid (h) and HB-EGF CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the HBEGF locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by HB-EGF HDR Plasmid (h) and HB-EGF HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by HBEGF homology arms to support homology-directed repair at defined HBEGF target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.